Sparsentan is a newly approved drug by the FDA for the treatment of high-risk patients with IgA Nephropathy. It has a unique mechanism of action as it blocks two receptors simultaneously:
The PROTECT trial demonstrated its efficacy in lowering proteinuria in patients with IgA nephropathy who were excreting proteins @ more than 1.5 gm/g of creatinine.
However, whether it protects the progression of IgA nephropathy to ESRD or advancing kidney disease is not yet clear.